We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Protalix (PLX) to Report Q1 Earnings: What's in the Cards?
Read MoreHide Full Article
Protalix BioTherapeutics, Inc. is scheduled to report first-quarter 2019 results on May 6.
The company has surpassed expectations in two of the previous four quarters, the average earnings positive surprise being 22.50%.
Protalix’s share price has increased 36% compared with the industry’s growth of 4% year to date.
Let's see how things are shaping up for this announcement.
Factors to Consider
Protalix is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. The company is developing its lead candidate Pegunigalsidase alfa (PRX-102) for the treatment of Fabry Disease.
The company expects to provide light on the revenues of its first commercial drug product, Elelyso, which marketed for the treatment of Gaucher Disease.
The company had a very productive meeting with the FDA to discuss the potential filing of an application for accelerated approval of PRX-102 and, at the FDA’s reques,t the company intends to hold a follow up meeting by the end of the second quarter of 2019 to discuss the data and content of the potential filing for accelerated approval.
In 2018, the company reported positive results from its phase II study of OPRX-106 for the treatment of ulcerative colitis.
We expect the company to throw more light other pipeline updates.
What Our Model Indicates
Our proven model does not conclusively show that Protalix is likely to beat on earnings in the to-be-reported quarter. This is because a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Earnings ESP: Protalix has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Protalix BioTherapeutics, Inc. Price and EPS Surprise
Zacks Rank: The company carries a Zacks Rank #3, which increases the predictive power of ESP. However, we need to have a positive Earnings ESP to be confident of an earnings beat.
Note that Sell-rated stocks (Zacks Rank #4 or 5) going into an earnings announcement are best avoided.
Stocks That Warrant a Look
Here are some stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Amgen Inc. (AMGN - Free Report) has an Earnings ESP of +0.12% and a Zacks Rank #3. The company is scheduled to release first-quarter 2019 results on May 7.
Inovio Pharmaceuticals, Inc. (INO - Free Report) has an Earnings ESP of +13.79% and a Zacks Rank #3.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
Image: Bigstock
Protalix (PLX) to Report Q1 Earnings: What's in the Cards?
Protalix BioTherapeutics, Inc. is scheduled to report first-quarter 2019 results on May 6.
The company has surpassed expectations in two of the previous four quarters, the average earnings positive surprise being 22.50%.
Protalix’s share price has increased 36% compared with the industry’s growth of 4% year to date.
Let's see how things are shaping up for this announcement.
Factors to Consider
Protalix is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. The company is developing its lead candidate Pegunigalsidase alfa (PRX-102) for the treatment of Fabry Disease.
The company expects to provide light on the revenues of its first commercial drug product, Elelyso, which marketed for the treatment of Gaucher Disease.
The company had a very productive meeting with the FDA to discuss the potential filing of an application for accelerated approval of PRX-102 and, at the FDA’s reques,t the company intends to hold a follow up meeting by the end of the second quarter of 2019 to discuss the data and content of the potential filing for accelerated approval.
In 2018, the company reported positive results from its phase II study of OPRX-106 for the treatment of ulcerative colitis.
We expect the company to throw more light other pipeline updates.
What Our Model Indicates
Our proven model does not conclusively show that Protalix is likely to beat on earnings in the to-be-reported quarter. This is because a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to be able to beat estimates. But that is not the case here, as you will see below.
Earnings ESP: Protalix has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Protalix BioTherapeutics, Inc. Price and EPS Surprise
Protalix BioTherapeutics, Inc. Price and EPS Surprise | Protalix BioTherapeutics, Inc. Quote
Zacks Rank: The company carries a Zacks Rank #3, which increases the predictive power of ESP. However, we need to have a positive Earnings ESP to be confident of an earnings beat.
Note that Sell-rated stocks (Zacks Rank #4 or 5) going into an earnings announcement are best avoided.
Stocks That Warrant a Look
Here are some stocks you may want to consider, as our model shows that these have the right combination of elements to post an earnings beat this quarter.
Ultragenyx Pharmaceuticals Inc. (RARE - Free Report) has an Earnings ESP of +6.36% and a Zacks Rank #2. You can see the complete list of today’s Zacks #1 Rank stocks here.
Amgen Inc. (AMGN - Free Report) has an Earnings ESP of +0.12% and a Zacks Rank #3. The company is scheduled to release first-quarter 2019 results on May 7.
Inovio Pharmaceuticals, Inc. (INO - Free Report) has an Earnings ESP of +13.79% and a Zacks Rank #3.
Zacks' Top 10 Stocks for 2019
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-holds for the year?
Who wouldn't? Our annual Top 10s have beaten the market with amazing regularity. In 2018, while the market dropped -5.2%, the portfolio scored well into double-digits overall with individual stocks rising as high as +61.5%. And from 2012-2017, while the market boomed +126.3, Zacks' Top 10s reached an even more sensational +181.9%.
See Latest Stocks Today >>